Related Experiment Video
Updated: Jun 17, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Prevalence of KRAS amplification in patients with metastatic cancer: Real-world next-generation sequencing analysis
Dae-Ho Choi1, Hye-Lim Jang2, Sung Hee Lim1
1Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Background:
The Kirsten rat sarcoma virus (KRAS) is a prominent proto-oncogene. Several treatments for KRAS mutations have been developed. However, KRAS amplification, a KRAS alteration, is poorly understood, and there is currently no appropriate treatment other than conventional chemotherapy. This study aimed to elucidate the role of KRAS amplification in different types of cancers.
Methods:
From October 2019 to June 2023, we performed next-generation sequencing using Trusight Oncology 500 on 3895 patients with 37 different cancer types at the Samsung Medical Center. We analyzed the distribution of KRAS amplification according to cancer type and its correlation with tumor mutation burden (TMB). Concomitant KRAS mutations were also identified.
Results:
Of the total 3895 patients, 99 (2.5 %) had KRAS amplification. The highest frequency of KRAS amplification was detected in 2 % (27/1350) of patients with colorectal cancer, followed by 3.48 % (32/920) of patients with gastric cancer and 3.88 % (9/232) patients with of pancreatic cancer. MSI-High was not detected in patients with KRAS amplification. There was no correlation between KRAS copy number variation and TMB status. Among patients with KRAS amplification, 27.3 % (27/99) had a concomitant KRAS mutation. More than 50 % of patients had G12D or G12V mutations. In gastric cancer, patients with both KRAS amplification and mutation were extremely rare at 3.1 % (1/32); however, in colorectal cancer, more than half of the patients had KRAS amplification and mutation (51.9 %, 14/27). KRAS amplification and mutations are associated with mutations in tumor suppressor genes TP53, BRCA2, ARID1B, and PTCH1.
Conclusions:
Of the 3895 patients with metastatic solid tumors, 99 (2.5 %) had KRAS amplification, and next-generation sequencing analysis provided a deeper understanding of KRAS amplification.
Insights
KRAS amplification occurs in 2.5% of metastatic solid tumors. This genetic alteration, particularly in colorectal and gastric cancers, is linked to specific mutations and warrants further investigation for targeted therapies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The Kirsten rat sarcoma virus (KRAS) proto-oncogene is crucial in cell signaling.
- While KRAS mutations are targeted by therapies, KRAS amplification remains poorly understood and lacks specific treatments.
- This study investigates the role and prevalence of KRAS amplification across various cancer types.
Purpose of the Study:
- To determine the frequency and distribution of KRAS amplification in a large cohort of cancer patients.
- To explore the correlation between KRAS amplification, tumor mutation burden (TMB), and concomitant KRAS mutations.
- To identify potential associations between KRAS amplification and mutations in other key genes.
Main Methods:
- Next-generation sequencing (NGS) using Trusight Oncology 500 was performed on 3895 patients with 37 cancer types.
- Data were analyzed for KRAS amplification frequency, distribution by cancer type, and correlation with TMB.
- Concomitant KRAS mutations and co-occurring mutations in tumor suppressor genes were identified.
Main Results:
- KRAS amplification was identified in 2.5% (99/3895) of patients, with higher frequencies in pancreatic (3.88%), gastric (3.48%), and colorectal (2%) cancers.
- No correlation was found between KRAS copy number variation and TMB.
- Concomitant KRAS mutations (G12D, G12V) were observed in 27.3% of amplified cases, notably frequent in colorectal cancer (51.9%).
- KRAS amplification was associated with mutations in TP53, BRCA2, ARID1B, and PTCH1.
Conclusions:
- KRAS amplification is an actionable alteration present in 2.5% of metastatic solid tumors.
- NGS analysis provides valuable insights into the landscape of KRAS amplification and its co-occurring genetic events.
- Understanding these patterns may pave the way for novel therapeutic strategies targeting KRAS amplification.
More Related Videos
09:49Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
Published on: July 5, 2019
11:20Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology
Published on: March 21, 2018
